Bilgimol JC, Ragupathi S, Vengadassalapathy L, Senthil NS, Selvakumar K, Ganesan M, Manjunath SR. Stem cells: An eventual treatment option for heart diseases. World J Stem Cells 2015; 7(8): 1118-1126 [PMID: 26435771 DOI: 10.4252/wjsc.v7.i8.1118]
Corresponding Author of This Article
Sadananda Rao Manjunath, Scientist, KMS Health Centre Private Limited, No. 50, 51, Balaji Nagar, 3rd Street, Padi, Chennai 600050, Tamilnadu, India. manjunath.s@microtheraps.com
Research Domain of This Article
Cell Biology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Sep 26, 2015; 7(8): 1118-1126 Published online Sep 26, 2015. doi: 10.4252/wjsc.v7.i8.1118
Stem cells: An eventual treatment option for heart diseases
Joseph C Bilgimol, Subbareddy Ragupathi, Lakshmanan Vengadassalapathy, Nathan S Senthil, Kalimuthu Selvakumar, M Ganesan, Sadananda Rao Manjunath
Joseph C Bilgimol, M Ganesan, Sadananda Rao Manjunath, Micro Therapeutic Research Labs Private Limited, Chennai 600059, Tamilnadu, India
Joseph C Bilgimol, Lakshmanan Vengadassalapathy, Kalimuthu Selvakumar, M Ganesan, Sadananda Rao Manjunath, KMS Health Centre Private Limited, Chennai 600050, Tamilnadu, India
Subbareddy Ragupathi, Chettinad Hospital, Chennai 603103, Tamilnadu, India
Nathan S Senthil, Thermo Fisher Scientific India Private Limited, Chennai 600034, Tamilnadu, India
Author contributions: Bilgimol JC, Senthil NS and Manjunath SR prepared the paper; Ragupathi S and Vengadassalapathy L provided administrative, technical and supervisory support; Selvakumar K and Ganesan M reviewed and edited the paper.
Conflict-of-interest statement: Authors declare no potential conflict of interest towards the publication of this review article.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Sadananda Rao Manjunath, Scientist, KMS Health Centre Private Limited, No. 50, 51, Balaji Nagar, 3rd Street, Padi, Chennai 600050, Tamilnadu, India. manjunath.s@microtheraps.com
Telephone: +91-44-26543424 Fax: +91-44-22390068
Received: May 18, 2015 Peer-review started: May 20, 2015 First decision: June 24, 2015 Revised: July 4, 2015 Accepted: July 29, 2015 Article in press: August 3, 2015 Published online: September 26, 2015
Abstract
Stem cells are of global excitement for various diseases including heart diseases. It is worth to understand the mechanism or role of stem cells in the treatment of heart failure. Bone marrow derived stem cells are commonly practiced with an aim to improve the function of the heart. The majority of studies have been conducted with acute myocardial infarction and a few has been investigated with the use of stem cells for treating chronic or dilated cardiomyopathy. Heterogeneity in the treated group using stem cells has greatly emerged. Ever increasing demand for any alternative made is of at most priority for cardiomyopathy. Stem cells are of top priority with the current impact that has generated among physicians. However, meticulous selection of proper source is required since redundancy is clearly evident with the present survey. This review focuses on the methods adopted using stem cells for heart diseases and outcomes that are generated so far with an idea to determine the best therapeutic possibility in order to fulfill the present demand.
Core tip: Heart diseases are most common all over the world and any form of treatment would be well appreciated to enable successful well-being in the patients. Though there are enormous efforts attempted to handle heart diseases, there has been no propounded evidence so far to utilize a particular source of cells globally. In this regard, if the responses all over the world are collectively segregated to a global database, there may be options to identify the best suitable cell source that provides effective cure.
